Pattern of first recurrent lesions in pancreatic cancer: Hepatic relapse is associated with dismal prognosis and portal vein invasion

Hepato-Gastroenterology

Volumn 61, Issue 134, 2014, Pages 1756-1761

  Suenaga, Masaya ^a   Fujii, Tsutomu ^a   Kanda, Mitsuro ^a   Takami, Hideki ^a   Okumura, Norio ^a   Inokawa, Yoshikuni ^a   Kobayashi, Daisuke ^a   Tanaka, Chie ^a   Yamada, Suguru ^a   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic relapse; Pancreatic cancer; Portal vein invasion; Prognostic factor; Relapse pattern

Indexed keywords

FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREAS RESECTION; PORTAL VEIN; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK FACTOR; TUMOR INVASION; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PORTAL VEIN; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906963244     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13637     Document Type: Article

References (32)

1. Raimondi S, Maisonneuve P, Lowenfels AB: Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6:699-708.
2. Vincent A, Herman J, Schulick R, et al.: Pancreatic cancer. Lancet 2011; 378:607-620.
3. Cleary SP, Gryfe R, Guindi M, et al.: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198:722-731. (Pubitemid 38542900)
4. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-579.
5. Kanda M, Fujii T, Nagai S, et al.: Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas 2011; 40:951-955.
6. O'Reilly EM, Lowery MA: Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. Cancer J 2012; 18:609-613.
7. Nagai S, Fujii T, Kodera Y, et al.: Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Ann Surg Oncol 2011; 18:2329-2337.
8. Kanda M, Fujii T, Sahin TT, et al.: Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg 2010; 251:483-487.
9. Willett CG, Czito BG, Bendell JC, Ryan DP: Locally advanced pancreatic cancer. J Clin Oncol 2005; 23:4538-4544. (Pubitemid 46196584)
10. Kanda M, Takeda S, Yamada S, et al.: Operative treatment of pancreatic ductal adenocarcinoma with extensive portal venous tumor embolism. Pancreas 2010; 39:268-269.
11. Chun YS, Milestone BN, Watson JC, et al.: Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010; 17:2832-2838.
12. Zyromski NJ, Howard TJ: Acute superior mesenteric-portal vein thrombosis after pancreaticoduodenectomy: treatment by operative thrombectomy. Surgery 2008; 143:566-567.
13. Tang D, Zhang JQ, Wang DR: Long term results of pancreatectomy with portal-superior mesenteric vein resection for pancreatic carcinoma: a systematic review. Hepatogastroenterology 2011;58:623-631.
14. Poon RT, Fan ST, Lo CM, et al.: Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement World J Surg 2004; 28:602-608. (Pubitemid 38802799)
15. Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant tumours. 7th ed. Wiley-Blackwell, New York, 2009; pp.132-135.
16. Nakao A, Kanzaki A, Fujii T, et al.: Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg 2012; 255:103-108.
17. Trouilloud I, Dubreuil O, Boussaha T, et al.: Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 2011; 35:364-374.
18. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-1210. (Pubitemid 38339364)
19. Burris HA, 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
20. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-3275. (Pubitemid 34831525)
21. Colucci G, Labianca R, Di Costanzo F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28:1645-1651.
22. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966. (Pubitemid 46972777)
23. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21:195-200. (Pubitemid 27053441)
24. Katz MH, Wang H, Fleming JB, et al.: Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16:836-847.
25. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-277. (Pubitemid 46143304)
26. Ueno H, Kosuge T, Matsuyama Y, et al.: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101:908-915.
27. Ohigashi H, Ishikawa O, Eguchi H, et al.: Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg 2009; 250:88-95.
28. Hoffman JP, Lipsitz S, Pisansky T, et al.: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16:317-323. (Pubitemid 28041615)
29. Evans DB, Varadhachary GR, Crane CH, et al.: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:3496-3502.
30. Heinrich S, Pestalozzi BC, Schafer M, et al.: Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:2526-2531.
31. Palmer DH, Stocken DD, Hewitt H, et al.: A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14:2088-2096. (Pubitemid 46988260)
32. Tempera MA, Arnoletti JP, Behrman SW, et al.: Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012; 10:703-713.